How will Gilead price CAR-T? With Kite buy, the top biotech joins Novartis in spotlight – FiercePharma
FiercePharma |
How will Gilead price CAR–T? With Kite buy, the top biotech joins Novartis in spotlight
FiercePharma Novartis will likely have to produce numbers first: It's positioned to reach the market ahead of Kite with its CAR–T with its med, CTL019, to treat pediatric and young adult patients with B-cell ALL. The drug won an FDA panel's unanimous backing in June. Being for the $11.9bn benefit of investors of Kite: Gilead jumps into CAR T Gilead Looks To Become The White Knight Of CAR–T Gilead agrees to buy Kite Pharma, leaping into CAR–T cancer therapy |
